KRAS and pancreatic ductal adenocarcinoma: In order to assess these parameters of tumor behavior in vivo in the context of a functional immune system, we turned to cells derived from mouse pancreatic ductal adenocarcinoma driven by KRas and p53 mutations (Hingorani et al., 2005).